Portfolio

  • Actinobac Biomed, Inc.
  • Affineti Biologics, Inc.
  • CellXplore
  • Celvive
  • Durin Technologies, Inc.
  • GeneAssess, Inc.
  • Longevica
  • MentiNova, Inc.
  • NovoPedics, Inc.
  • Snowdon, Inc.

Actinobac Biomed, Inc. is a new company that is developing pharmaceutical agents for the treatment of hematologic malignancies (leukemias and lymphomas), latent infections (HIV/AIDS and tuberculosis), and autoimmune diseases (rheumatoid arthritis, multiple sclerosis, Crohn’s disease, type 1 diabetes, lupus and psoriasis).

Its lead product, Leukothera, is a bacterial toxin which specifically targets and depletes disease related white blood cells (WBC) that exhibit activated Leukocyte Function Antigen-1 (LFA-1) receptor on their surface. Since normal WBC and other bodily tissues or organs do not possess activated LFA-1, minimal negative side effects are expected.

Although the company is exploring treatments for a variety of medical conditions, its highest priority is the development of Leukothera as a protein therapeutic for the treatment of hematologic malignancies, especially acute myeloid leukemia and B-cell lymphoma. Research efforts to develop peptides or small molecules that target LFA-1 and act in a similar manner to Leukothera are also underway to expand Actinobac’s pipeline of pharmaceutical agents.

For more information, visit www.actinobac.com or call (908) 731-6610.

Affineti Biologics, Inc. is working to advance the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine.

Positive results from studies by the company for anticaries and periodontal therapy look promising in their ability to affect plaque reduction, influencing dental hygiene and systemic medicine.

Affineti founder Dr. Daniel Fine, a professor and chair in the Department of Oral Biology at UMDNJ-New Jersey Dental School, believes the development of products based on his research will prove more effective than others currently available.

His group uses biological principals to create hybrid or fusion proteins that adhere to tissues with potent but non-toxic antimicrobial effects. He hopes to use these proteins to deliver effective substances locally, avoiding systemic complications. In the short term, Dr. Fine plans to use these proteins in conditions related to the oral cavity and then expand to include mucosal infections in other sites throughout the body.

The company is currently focused on developing a more effective mouthwash for anticaries and periodontal disease therapy and hopes to move to clinical trials shortly.

For more information, call (908) 731-6610.

CellXplore is a privately held biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable, and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.

The company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.

CellXplore’s platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer’s disease, Parkinson’s disease and inflammatory diseases.

For more information, visit www.cellxplore.com or call (908) 731-6610.

Celvive is a start-up company working to improve the quality of life for patients with chronic spinal cord injuries (SCI) by developing new cell therapy treatment methods using adult stem cells that possess the ability to enhance regeneration of spinal nerves.

Celvive founder Dr. Hatem Sabaawy has also developed technology to isolate adult stem cells from patients by passing them through a sealed multiple-bag device and delivering the cells directly near the patient’s injury site. Further development will permit using this technology to isolate and deliver stem cells for multiple regenerative medicine applications.

Celvive has promising data with this therapy in experimental dogs and SCI patients. These preclinical studies in a canine model revealed that these stem cells homed to the injury site, resulting in neural regeneration, functional improvement, and importantly, with no side effects observed (manuscript submitted). This led the company to initiate an overseas, randomized controlled phase I/II trial in humans including 70 chronic SCI patients. Data from these studies indicate the safety and efficacy of intrathecal autologous stem cell therapy. The results from these preclinical and clinical trial studies will be published shortly.

Dr. Sabaawy hopes to quickly advance to a point where he can embark on FDA clinical trials shortly.

For more information, call (908) 731-6610 or visit www.celvive.com.

Durin Technologies, Inc. is a start-up company focused on the development of blood tests to diagnose and monitor the progress of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.

The company’s technology is based upon the discovery that human blood contains many different autoantibodies. The number and levels of these autoantibodies essentially remain constant throughout a person’s life until a disease or medical condition cause changes to occur. By identifying the patterns of the disease related changes to a patient’s autoantibody profile, specific neurodegenerative diseases can be diagnosed and their progress monitored. Since only a small drop of blood is required for testing and the results can be easily analyzed, this technology provides a minimally intrusive and rapid diagnostic methodology.

The founder of Durin Technologies, Dr. Robert Nagele, hopes that these results will not only provide diagnostic products but can lead to the development of new therapies to both slow the progression of neurodegenerative diseases and perhaps even circumvent these devastating illnesses altogether.

Supported by clinical trial results, the success of these products will fulfill an unmet need in the diagnostic and pharmaceutical industry.

For more information, call (908) 731-6610.

GeneAssess, Inc. is dedicated to developing its breakthrough discovery of the FRY gene as a predictive biomarker for breast and other cancers. The company will use proprietary antibodies to validate loss of the FRY protein as a cancer biomarker, detect genetic mutations in FRY associated high-risk populations and explore target validation for FRY. The signature gene could provide a more accurate diagnostic biomarker for cancer staging in breast and other types of cancer.

The company has an exclusive license to the intellectual property developed by founder Dr. Helmut Zarbl, a professor of environmental and occupational medicine at Robert Wood Johnson Medical School, a member of the Environmental and Occupational Health Sciences Institute (EOHSI), and the associate director for public health science at The Cancer Institute of New Jersey.

In research performed to date, mutations in the gene increased rat susceptibility to mammary cancer and FRY reduced the growth of highly aggressive human breast cancer cells in animal models. This tumor suppressor gene could also be useful for developing new targeted drugs, especially for the treatment of aggressive and/or advanced cancers originating from many tissue types.

For more information, call (908) 731-6610 or visit www.geneassessinc.com.

Longevica Pharmaceuticals, Inc., is a privately held biotechnology company that is developing novel, proprietary drugs with potential use in the treatment of cancer, degenerative diseases and age-related disorders. The company was formed primarily to commercialize the discoveries demonstrating that inactivation of an alpha kinase, EF2 kinase, protects normal (non-cancer) cells and tissues from the toxic effect of chemotherapy or radiation treatments.

Despite the tremendous progress in drug cancer chemotherapy, most of the drugs used today have a pronounced toxicity effect, killing normal cells along with cancer cells. The work being done by scientists at Longevica may lead to a novel approach in cancer therapy that can significantly improve the efficiency of the current methods of cancer treatment.

The discoveries are also expected to be helpful in treating patients suffering from ischemia, stroke and neurodegenerative disorders such as Alzheimer’s disease by protecting cells and tissues from stress damage.

Foundation Venture Capital Group sold its equity interest in Longevica to Rostock International Ltd., a subsidiary of Rostock Group, a Moscow (Russia) headquartered global investment firm focused on investments in breakthrough technologies that can radically increase human lifespan and improve quality of life. The sale to Rostock International represented a substantial return on investment in less than 18 months.

For more information, call (908) 731-6610.

MentiNova, Inc. is a start-up working to treat L-Dopa Induced Dyskinesia (LID), a major side effect of Parkinson’s disease therapeutics. This is achieved by exploring an oral medication that could reduce these uncontrollable, often chaotic, disabling movements in patients being treated with L-Dopa.

Dr. M. Maral Mouradian, company co-founder, formed MentiNova to focus on use of a drug that is currently clinically approved and repurpose it for the treatment of LID in patients with Parkinson’s disease. Clinical advancement of this compound will lead to rapid availability for patients who desperately need an effective therapy. Dr. Mouradian hopes to be able to subsequently extend its utility for patients with other conditions characterized by involuntary movements such as Tourette’s syndrome, Huntington’s disease and Tardive Dyskinesia.

Research to date has already provided in vivo proof of principle data and the company is advancing with its clinical program.

For more information, call (908) 731-6610.

Snowdon, Inc. is a drug discovery and development company that is focused on three major therapeutic areas with substantial market potential—cancer, acute and chronic pain, and infectious diseases. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates that address the urgent need for safe and effective medicine.

Snowdon’s proven discovery platform is built for speed, economy and maximum success rate. They employ a battery of proprietary computational tools to rapidly identify high-value molecules from their fast in silico library of vendor-available compounds, which can then be procured for initial biological proof of concept evaluation studies.

For more information, visit www.snowdonpharma.com or call (908) 731-6610.

NovoPedics, Inc., is developing an implantable meniscus replacement/regeneration medical device that uses a biodegradable polymer fiber-reinforced scaffold that restores mobility to patients suffering from severe meniscus knee injuries and can prevent the long-term development of arthritis that so often occurs as a result of meniscus knee surgery.

Its first product, Meniscofix™, provides an innovative way to repair with a unique fiber-reinforced design similar to the native meniscus and can be attached to either soft tissue or bone, allowing it to be used in either partial or total meniscus replacement surgery.

Pre-clinical studies leading to the creation of the company have shown strong results to date.

According to company founders Dr. Michael Dunn and Dr. Charles Gatt, there are currently no FDA-approved products for replacement of the meniscus to help the more than 800,000 individuals who annually undergo meniscectomies in the US each year.

For more information, call (908) 731-6610.